Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Clinical trial NCT04476459 · UNKNOWN

Trial details

NCT number: NCT04476459
Sponsor: Huiqiang Huang
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Follicular Lymphoma Grade IIIb Transformed Lymphoma EBV-Positive DLBCL, Nos ALK-Positive Anaplastic Large Cell Lymphoma

Start date: 2020-07-23
Primary completion: 2022-08-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.